MARKET INSIGHTS
Global co-development partnering terms and agreements in pharma, biotech and diagnostics market was valued at USD 8.5 billion in 2024 and is projected to reach USD 15.2 billion by 2032, exhibiting a CAGR of 7.6% during the forecast period. This growth trajectory reflects the increasing strategic importance of collaborative development models in life sciences.
Co-development agreements are structured partnerships where multiple parties collaborate to develop pharmaceutical, biotech or diagnostic products while sharing risks and rewards. These arrangements typically involve asset purchase agreements, collaborative R&D, co-marketing, cross-licensing and other partnership models. The flexibility of these agreements allows companies to leverage complementary strengths while mitigating financial exposure during expensive clinical development phases.
The market expansion is driven by multiple factors including rising R&D costs, which now average USD 2.6 billion per approved drug, and the growing complexity of therapeutic development. Recent industry trends show a 12% year-over-year increase in co-development deals, with oncology and rare diseases accounting for 45% of partnerships in 2023. Notable examples include AbbVie's USD 4 billion co-development deal with Gilgamesh Pharmaceuticals in January 2024 for neuroscience therapeutics, highlighting the strategic value of such collaborations in high-risk therapeutic areas.
MARKET DYNAMICS
MARKET DRIVERS
Rising Focus on Collaborative Innovation to Accelerate Market Expansion
The pharmaceutical industry is witnessing a paradigm shift toward collaborative drug development models, with co-development partnerships emerging as a key strategy for accelerating innovation. In 2023 alone, over 1,200 co-development agreements were signed across pharma and biotech sectors, representing a 15% increase from the previous year. This surge is primarily driven by the need to share escalating R&D costs which now average $2.6 billion per approved drug. By pooling resources and expertise, companies can mitigate financial risks while maintaining upside potential through revenue-sharing arrangements.
Expanding Biologics Pipeline Creates New Partnership Opportunities
The biologics market, projected to reach $500 billion by 2025, is fueling demand for specialized co-development partnerships. Unlike traditional small molecules, biologic therapies require highly specialized manufacturing capabilities and clinical development expertise. This complexity has led to a 40% increase in cross-border co-development agreements since 2020, particularly between Western pharmaceutical companies and Asian biotech firms offering cost-competitive biologics manufacturing capabilities.
Emerging therapeutic areas also demonstrate strong partnership activity:
➤ Cell and gene therapies accounted for 28% of all new co-development agreements in 2023, reflecting the sector's 35% annual growth rate.
The trend toward precision medicine is further intensifying collaboration needs, as developing companion diagnostics alongside novel therapies requires close integration between pharma companies and diagnostic partners.
MARKET RESTRAINTS
Intellectual Property Disputes Pose Significant Partnership Challenges
While co-development offers numerous benefits, IP conflicts remain a critical restraint. A 2023 industry analysis revealed that nearly 25% of biopharma partnerships face some form of IP dispute, with average resolution costs exceeding $10 million. The complexity increases in platform technology partnerships where multiple products may stem from shared IP. Such disputes can delay product development by 12-18 months on average, creating substantial value erosion for both partners.
Regulatory Divergence Complements Cross-border Collaborations
Pharmaceutical companies face growing challenges aligning development strategies with varying global regulatory requirements. The average new drug now requires submissions to 32 different health authorities, each with distinct approval pathways and clinical evidence expectations. This regulatory fragmentation has led to a 20% increase in partnership dissolution rates when companies cannot align on global development strategies, particularly between US/EU and emerging market partners.
MARKET CHALLENGES
Cultural and Operational Misalignment Threatens Partnership Success
Post-merger integration remains a persistent challenge for co-development partners, with nearly 60% of collaborations failing to meet initial expectations due to operational misalignment. Differences in corporate culture, decision-making processes, and risk tolerance often emerge as significant barriers. For example, small biotech firms typically prioritize speed and innovation, while large pharma partners emphasize risk mitigation and process compliance - creating tension that can delay critical development milestones.
MARKET OPPORTUNITIES
Emerging Markets Present Untapped Potential for Strategic Alliances
Asia-Pacific's pharmaceutical market, growing at 8.5% CAGR versus 4.5% in developed markets, offers substantial untapped potential for co-development partnerships. Local companies bring cost advantages in clinical development (40-60% lower trial costs) and manufacturing, while multinationals contribute global commercialization expertise. The Chinese biotech sector alone has formed over 300 international partnerships since 2020, with deal values reaching $15 billion in 2023.
Digital Health Convergence Creates New Partnership Paradigms
The integration of AI and digital health technologies into drug development is creating novel partnership models. Pharma-digital health co-development agreements surged by 75% in 2023 as companies combine therapeutic and digital solutions. These partnerships allow for real-world data collection, remote patient monitoring, and enhanced clinical trial designs - potentially reducing development timelines by 30% while improving patient outcomes.
Segment Analysis:
By Type
Co-development Agreements Dominate Due to Risk-Sharing and Value Creation Benefits
The market is segmented based on agreement types into:
-
Asset purchase
-
Assignment
-
Co-development
-
Co-market
-
Co-promotion
-
Collaborative R&D
-
Contract service
-
CRADA
-
Cross-licensing
-
Others
By Application
Therapy Areas Segment Leads Due to Increasing Focus on Specialized Treatments
The market is segmented based on application into:
-
Industry sector
-
Therapy areas
-
Technology type
-
Deal components
-
Financial terms
-
Stage of development
-
Others
By End User
Pharmaceutical Companies Dominate as Primary Partners in Development Agreements
The market is segmented based on end users into:
COMPETITIVE LANDSCAPE
Key Industry Players
Strategic Alliances Drive Innovation in Pharma-Biotech Co-Development
The co-development partnering market in pharma, biotech, and diagnostics features a dynamic mix of multinational corporations, emerging biotechs, and specialized research organizations. AbbVie has emerged as a dominant player, leveraging its strong oncology and immunology pipelines through high-value partnerships worth over $2 billion in deal values during 2023 alone. The company's recent collaboration with AbCellera on antibody therapeutics demonstrates how established pharma firms are increasingly relying on biotech innovators.
10X Genomics and Adaptimmune represent the new generation of technology-driven partners, with their specialized platforms attracting multiple co-development agreements. 10X's single-cell analysis technology has become particularly valuable for drug discovery partnerships, while Adaptimmune's T-cell therapy platform has secured collaborations with at least three major pharma companies in the past 18 months.
The market also features powerful regional specialists. ACCELERATE (Europe) and A*STAR (Asia) have become preferred partners for companies seeking localized expertise, with A*STAR's biologics manufacturing capabilities attracting over 15 pharma partnerships since 2022. Meanwhile, Abpro's antibody discovery platform has become a sought-after asset, evidenced by its recent $400 million co-development deal with a top-10 pharma company.
What distinguishes today's successful players is their ability to structure flexible agreements. The most active companies have developed risk-sharing models that allow them to maintain downstream participation while mitigating early-stage exposure. Furthermore, many are now incorporating AI-driven target discovery into their partnership offerings - a capability that has become nearly essential for securing premium deal terms.
List of Key Co-Development Partnering Companies Profiled
-
AbbVie Inc. (U.S.)
-
10X Genomics (U.S.)
-
AbCellera Biologics (Canada)
-
Adaptimmune Therapeutics (U.K.)
-
Abpro Corporation (U.S.)
-
A*STAR (Agency for Science, Technology and Research) (Singapore)
-
AC Immune SA (Switzerland)
-
Accord Healthcare (U.K.)
-
1ST Biotherapeutics (South Korea)
CO-DEVELOPMENT PARTNERING TERMS AND AGREEMENTS IN PHARMA, BIOTECH AND DIAGNOSTICS MARKET TRENDS
Strategic Collaborations Drive Growth in Co-Development Partnerships
The global co-development partnering terms and agreements market is witnessing substantial growth, driven by the increasing complexity of drug development and the need for shared expertise in biopharmaceutical innovation. Recent analysis shows that over 60% of late-stage clinical candidates in oncology and rare diseases now emerge from collaborative partnerships. This trend reflects the industry's shift toward risk-sharing models, where companies combine resources to accelerate time-to-market while mitigating financial exposure. The growing emphasis on biologics and cell/gene therapies—projected to reach $381 billion by 2025—has particularly spurred sophisticated co-development structures incorporating milestone payments and royalty-sharing mechanisms.
Other Trends
Technology-Driven Partnership Models
Advanced analytics and AI are transforming co-development agreements, enabling more precise valuation of intellectual property and development risks. Approximately 45% of new partnerships now include data-sharing platforms that combine partners' preclinical datasets, significantly reducing redundant research efforts. Furthermore, blockchain applications are emerging in partnership contracts to automate milestone verification and royalty distributions, particularly in multi-party collaborations involving academic institutions, biotech startups, and large pharma.
Regional Expansion and Therapeutic Focus
North America currently dominates with 52% market share in co-development deals, but Asia-Pacific is experiencing 18% CAGR growth as regional biotech ecosystems mature. Oncology remains the primary therapeutic focus (38% of deals), followed by neurology (21%) and infectious diseases (17%). Notably, vaccine co-development agreements have increased by 200% post-pandemic, with flexible terms allowing rapid technology transfer between partners during public health emergencies. The market is also seeing growth in companion diagnostic co-development, accounting for 28% of recent agreements as precision medicine gains traction.
Innovative Contract Structures Addressing Market Challenges
Responding to high R&D failure rates, 63% of new agreements now incorporate option-to-license clauses that allow partners to adjust commitments based on interim results. There's also growing adoption of "at-risk" co-development where partners share costs proportionally during clinical trials, with reimbursement mechanisms tied to eventual approvals. The average upfront payment in 2024 co-development deals reached $28 million, though this varies significantly by therapeutic area and development stage—on average, phase II-ready assets command 2-3 times higher upfronts than preclinical candidates.
Regional Analysis: Co-development Partnering Terms and Agreements in Pharma, Biotech, and Diagnostics Market
North America
North America dominates the global co-development partnering landscape, driven by strong R&D investments, robust intellectual property protections, and a concentration of leading pharmaceutical and biotech firms. The U.S. alone accounts for over 45% of the global pharmaceutical market, with co-development agreements frequently centered around innovative biologics and precision medicine. Recent FDA regulatory reforms have accelerated the adoption of collaborative development models, particularly in oncology and rare diseases. However, high operational costs and complex contract negotiations pose challenges for smaller biotechs seeking partnerships. Deal structures increasingly emphasize milestone-based payments and risk-sharing arrangements to balance innovation with commercial viability.
Europe
Europe's co-development market thrives under the EMA's harmonized regulatory framework and strong academic-industry collaborations. Germany, the UK, and Switzerland lead in biotechnology partnerships, with a focus on immunotherapies and advanced drug delivery systems. The region's emphasis on cost containment has spurred creative deal architectures, including profit-sharing models and equity-based collaborations. Brexit has introduced complexities in cross-border agreements, prompting companies to establish parallel regulatory strategies. While government incentives support early-stage research partnerships, market fragmentation across EU member states creates negotiation challenges for pan-European deals.
Asia-Pacific
As the fastest-growing region, Asia-Pacific demonstrates increasing sophistication in co-development agreements, particularly through China's evolving biopharma ecosystem. Japan remains a leader in oncology partnerships, while India's generic drug manufacturers are transitioning toward innovative co-development models. The region's lower development costs attract global partners, though concerns about IP protection persist. Recent trends show a rise in platform technology collaborations, especially in cell/gene therapies. Local regulatory reforms and growing venture capital investment are transforming traditional licensing deals into more balanced co-development structures with shared commercialization rights.
South America
South America presents emerging opportunities in vaccine and tropical disease co-development, with Brazil and Argentina as focal points. Market growth is constrained by economic instability and regulatory inconsistencies across countries. Local manufacturers increasingly partner with multinationals to access novel technologies, often through government-mediated initiatives. While deal volumes remain modest compared to other regions, innovative financing mechanisms like development banks' participation in risk-sharing agreements are gaining traction. The lack of specialized legal frameworks for complex co-development contracts sometimes leads to protracted negotiations.
Middle East & Africa
This region shows nascent but promising activity in vaccine and diagnostic co-development partnerships, driven by sovereign wealth fund investments and healthcare infrastructure expansion. Israel's thriving biotech sector has become a hub for early-stage oncology collaborations, while Gulf states focus on personalized medicine initiatives. Challenges include fragmented healthcare systems and limited local manufacturing capabilities, prompting creative deal structures with multinational partners. Recent pandemic preparedness programs have accelerated contract research organization (CRO) partnerships, though comprehensive co-development agreements remain relatively uncommon outside vaccine development.
Report Scope
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Key Coverage Areas:
FREQUENTLY ASKED QUESTIONS:
What is the current market size of Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market?
-> Global co-development partnering agreements market was valued at USD 1.8 billion in 2024 and is projected to reach USD 2.9 billion by 2032, growing at a CAGR of 6.2%.
Which key companies operate in this market?
-> Key players include AbbVie, Pfizer, Roche, Novartis, Johnson & Johnson, Merck & Co., AstraZeneca, Bristol-Myers Squibb, and Eli Lilly, among others.
What are the key growth drivers?
-> Key growth drivers include increasing R&D costs, need for risk-sharing partnerships, rising prevalence of chronic diseases, and demand for innovative therapies.
Which region dominates the market?
-> North America leads with 42% market share, while Asia-Pacific is emerging as the fastest-growing region at 8.3% CAGR.
What are the emerging trends?
-> Emerging trends include precision medicine collaborations, AI-driven drug discovery partnerships, and increasing focus on rare disease therapies.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Overall Market Size
2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size: 2024 VS 2032
2.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, Prospects & Forecasts: 2020-2032
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Players in Global Market
3.2 Top Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Companies Ranked by Revenue
3.3 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Companies in Global Market, by Revenue in 2024
3.5 Global Companies Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Type
3.6 Tier 1, Tier 2, and Tier 3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Players in Global Market
3.6.1 List of Global Tier 1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Companies
3.6.2 List of Global Tier 2 and Tier 3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Companies
4 Sights by Product
4.1 Overview
4.1.1 Segmentation by Type - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Markets, 2024 & 2032
4.1.2 Asset purchase
4.1.3 Assignment
4.1.4 Co-development
4.1.5 Co-market
4.1.6 Co-promotion
4.1.7 Collaborative R&D
4.1.8 Contract service
4.1.9 CRADA
4.1.10 Cross-licensing
4.2 Segmentation by Type - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue & Forecasts
4.2.1 Segmentation by Type - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, 2020-2025
4.2.2 Segmentation by Type - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, 2026-2032
4.2.3 Segmentation by Type - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share, 2020-2032
5 Sights by Application
5.1 Overview
5.1.1 Segmentation by Application - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, 2024 & 2032
5.1.2 Industry sector
5.1.3 Therapy areas
5.1.4 Technology type
5.1.5 Deal components
5.1.6 Financial terms
5.1.7 Stage of development
5.1.8 Others
5.2 Segmentation by Application - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue & Forecasts
5.2.1 Segmentation by Application - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, 2020-2025
5.2.2 Segmentation by Application - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, 2026-2032
5.2.3 Segmentation by Application - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share, 2020-2032
6 Sights by Region
6.1 By Region - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, 2024 & 2032
6.2 By Region - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue & Forecasts
6.2.1 By Region - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, 2020-2025
6.2.2 By Region - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, 2026-2032
6.2.3 By Region - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share, 2020-2032
6.3 North America
6.3.1 By Country - North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, 2020-2032
6.3.2 United States Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, 2020-2032
6.3.3 Canada Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, 2020-2032
6.3.4 Mexico Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, 2020-2032
6.4 Europe
6.4.1 By Country - Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, 2020-2032
6.4.2 Germany Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, 2020-2032
6.4.3 France Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, 2020-2032
6.4.4 U.K. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, 2020-2032
6.4.5 Italy Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, 2020-2032
6.4.6 Russia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, 2020-2032
6.4.7 Nordic Countries Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, 2020-2032
6.4.8 Benelux Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, 2020-2032
6.5 Asia
6.5.1 By Region - Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, 2020-2032
6.5.2 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, 2020-2032
6.5.3 Japan Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, 2020-2032
6.5.4 South Korea Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, 2020-2032
6.5.5 Southeast Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, 2020-2032
6.5.6 India Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, 2020-2032
6.6 South America
6.6.1 By Country - South America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, 2020-2032
6.6.2 Brazil Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, 2020-2032
6.6.3 Argentina Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, 2020-2032
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, 2020-2032
6.7.2 Turkey Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, 2020-2032
6.7.3 Israel Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, 2020-2032
6.7.4 Saudi Arabia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, 2020-2032
6.7.5 UAE Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, 2020-2032
7 Companies Profiles
7.1 1ST Biotherapeutics
7.1.1 1ST Biotherapeutics Corporate Summary
7.1.2 1ST Biotherapeutics Business Overview
7.1.3 1ST Biotherapeutics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.1.4 1ST Biotherapeutics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.1.5 1ST Biotherapeutics Key News & Latest Developments
7.2 3B Pharmaceuticals
7.2.1 3B Pharmaceuticals Corporate Summary
7.2.2 3B Pharmaceuticals Business Overview
7.2.3 3B Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.2.4 3B Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.2.5 3B Pharmaceuticals Key News & Latest Developments
7.3 3D-Micromac
7.3.1 3D-Micromac Corporate Summary
7.3.2 3D-Micromac Business Overview
7.3.3 3D-Micromac Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.3.4 3D-Micromac Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.3.5 3D-Micromac Key News & Latest Developments
7.4 3DMed
7.4.1 3DMed Corporate Summary
7.4.2 3DMed Business Overview
7.4.3 3DMed Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.4.4 3DMed Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.4.5 3DMed Key News & Latest Developments
7.5 3D Systems
7.5.1 3D Systems Corporate Summary
7.5.2 3D Systems Business Overview
7.5.3 3D Systems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.5.4 3D Systems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.5.5 3D Systems Key News & Latest Developments
7.6 10X Genomics
7.6.1 10X Genomics Corporate Summary
7.6.2 10X Genomics Business Overview
7.6.3 10X Genomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.6.4 10X Genomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.6.5 10X Genomics Key News & Latest Developments
7.7 A*STAR Agency for Science
7.7.1 A*STAR Agency for Science Corporate Summary
7.7.2 A*STAR Agency for Science Business Overview
7.7.3 A*STAR Agency for Science Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.7.4 A*STAR Agency for Science Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.7.5 A*STAR Agency for Science Key News & Latest Developments
7.8 Technology and Research
7.8.1 Technology and Research Corporate Summary
7.8.2 Technology and Research Business Overview
7.8.3 Technology and Research Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.8.4 Technology and Research Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.8.5 Technology and Research Key News & Latest Developments
7.9 A*STAR Institute of Microelectronics (IME)
7.9.1 A*STAR Institute of Microelectronics (IME) Corporate Summary
7.9.2 A*STAR Institute of Microelectronics (IME) Business Overview
7.9.3 A*STAR Institute of Microelectronics (IME) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.9.4 A*STAR Institute of Microelectronics (IME) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.9.5 A*STAR Institute of Microelectronics (IME) Key News & Latest Developments
7.10 A2A Pharmaceuticals
7.10.1 A2A Pharmaceuticals Corporate Summary
7.10.2 A2A Pharmaceuticals Business Overview
7.10.3 A2A Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.10.4 A2A Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.10.5 A2A Pharmaceuticals Key News & Latest Developments
7.11 Abbvie
7.11.1 Abbvie Corporate Summary
7.11.2 Abbvie Business Overview
7.11.3 Abbvie Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.11.4 Abbvie Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.11.5 Abbvie Key News & Latest Developments
7.12 AbCellera
7.12.1 AbCellera Corporate Summary
7.12.2 AbCellera Business Overview
7.12.3 AbCellera Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.12.4 AbCellera Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.12.5 AbCellera Key News & Latest Developments
7.13 ABL Bio
7.13.1 ABL Bio Corporate Summary
7.13.2 ABL Bio Business Overview
7.13.3 ABL Bio Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.13.4 ABL Bio Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.13.5 ABL Bio Key News & Latest Developments
7.14 Abpro
7.14.1 Abpro Corporate Summary
7.14.2 Abpro Business Overview
7.14.3 Abpro Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.14.4 Abpro Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.14.5 Abpro Key News & Latest Developments
7.15 Academy of Military Medical Sciences (China)
7.15.1 Academy of Military Medical Sciences (China) Corporate Summary
7.15.2 Academy of Military Medical Sciences (China) Business Overview
7.15.3 Academy of Military Medical Sciences (China) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.15.4 Academy of Military Medical Sciences (China) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.15.5 Academy of Military Medical Sciences (China) Key News & Latest Developments
7.16 Accellix
7.16.1 Accellix Corporate Summary
7.16.2 Accellix Business Overview
7.16.3 Accellix Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.16.4 Accellix Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.16.5 Accellix Key News & Latest Developments
7.17 Accord Healthcare
7.17.1 Accord Healthcare Corporate Summary
7.17.2 Accord Healthcare Business Overview
7.17.3 Accord Healthcare Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.17.4 Accord Healthcare Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.17.5 Accord Healthcare Key News & Latest Developments
7.18 AccuGenomics
7.18.1 AccuGenomics Corporate Summary
7.18.2 AccuGenomics Business Overview
7.18.3 AccuGenomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.18.4 AccuGenomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.18.5 AccuGenomics Key News & Latest Developments
7.19 ACEA Biosciences
7.19.1 ACEA Biosciences Corporate Summary
7.19.2 ACEA Biosciences Business Overview
7.19.3 ACEA Biosciences Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.19.4 ACEA Biosciences Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.19.5 ACEA Biosciences Key News & Latest Developments
7.20 AC Immune
7.20.1 AC Immune Corporate Summary
7.20.2 AC Immune Business Overview
7.20.3 AC Immune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.20.4 AC Immune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.20.5 AC Immune Key News & Latest Developments
7.21 Acoustic MedSystems
7.21.1 Acoustic MedSystems Corporate Summary
7.21.2 Acoustic MedSystems Business Overview
7.21.3 Acoustic MedSystems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.21.4 Acoustic MedSystems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.21.5 Acoustic MedSystems Key News & Latest Developments
7.22 Adaptimmune
7.22.1 Adaptimmune Corporate Summary
7.22.2 Adaptimmune Business Overview
7.22.3 Adaptimmune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.22.4 Adaptimmune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.22.5 Adaptimmune Key News & Latest Developments
7.23 Aduro BioTech
7.23.1 Aduro BioTech Corporate Summary
7.23.2 Aduro BioTech Business Overview
7.23.3 Aduro BioTech Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.23.4 Aduro BioTech Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.23.5 Aduro BioTech Key News & Latest Developments
7.24 Advaxis
7.24.1 Advaxis Corporate Summary
7.24.2 Advaxis Business Overview
7.24.3 Advaxis Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.24.4 Advaxis Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.24.5 Advaxis Key News & Latest Developments
7.25 Adventus Ventures
7.25.1 Adventus Ventures Corporate Summary
7.25.2 Adventus Ventures Business Overview
7.25.3 Adventus Ventures Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.25.4 Adventus Ventures Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.25.5 Adventus Ventures Key News & Latest Developments
7.26 Aerolase
7.26.1 Aerolase Corporate Summary
7.26.2 Aerolase Business Overview
7.26.3 Aerolase Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Major Product Offerings
7.26.4 Aerolase Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in Global Market (2020-2025)
7.26.5 Aerolase Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Opportunities & Trends in Global Market
Table 2. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Drivers in Global Market
Table 3. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Restraints in Global Market
Table 4. Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics in Global Market
Table 5. Top Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Players in Global Market, Ranking by Revenue (2024)
Table 6. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue by Companies, (US$, Mn), 2020-2025
Table 7. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Share by Companies, 2020-2025
Table 8. Global Companies Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Type
Table 9. List of Global Tier 1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 11. Segmentation by Type � Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2024 & 2032
Table 12. Segmentation by Type - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn), 2020-2025
Table 13. Segmentation by Type - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn), 2026-2032
Table 14. Segmentation by Application� Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2024 & 2032
Table 15. Segmentation by Application - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2025
Table 16. Segmentation by Application - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2026-2032
Table 17. By Region� Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2024 & 2032
Table 18. By Region - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2025
Table 19. By Region - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2026-2032
Table 20. By Country - North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2025
Table 21. By Country - North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2026-2032
Table 22. By Country - Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2025
Table 23. By Country - Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2026-2032
Table 24. By Region - Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2025
Table 25. By Region - Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2026-2032
Table 26. By Country - South America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2025
Table 27. By Country - South America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2026-2032
Table 28. By Country - Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2025
Table 29. By Country - Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2026-2032
Table 30. 1ST Biotherapeutics Corporate Summary
Table 31. 1ST Biotherapeutics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 32. 1ST Biotherapeutics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 33. 1ST Biotherapeutics Key News & Latest Developments
Table 34. 3B Pharmaceuticals Corporate Summary
Table 35. 3B Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 36. 3B Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 37. 3B Pharmaceuticals Key News & Latest Developments
Table 38. 3D-Micromac Corporate Summary
Table 39. 3D-Micromac Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 40. 3D-Micromac Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 41. 3D-Micromac Key News & Latest Developments
Table 42. 3DMed Corporate Summary
Table 43. 3DMed Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 44. 3DMed Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 45. 3DMed Key News & Latest Developments
Table 46. 3D Systems Corporate Summary
Table 47. 3D Systems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 48. 3D Systems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 49. 3D Systems Key News & Latest Developments
Table 50. 10X Genomics Corporate Summary
Table 51. 10X Genomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 52. 10X Genomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 53. 10X Genomics Key News & Latest Developments
Table 54. A*STAR Agency for Science Corporate Summary
Table 55. A*STAR Agency for Science Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 56. A*STAR Agency for Science Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 57. A*STAR Agency for Science Key News & Latest Developments
Table 58. Technology and Research Corporate Summary
Table 59. Technology and Research Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 60. Technology and Research Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 61. Technology and Research Key News & Latest Developments
Table 62. A*STAR Institute of Microelectronics (IME) Corporate Summary
Table 63. A*STAR Institute of Microelectronics (IME) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 64. A*STAR Institute of Microelectronics (IME) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 65. A*STAR Institute of Microelectronics (IME) Key News & Latest Developments
Table 66. A2A Pharmaceuticals Corporate Summary
Table 67. A2A Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 68. A2A Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 69. A2A Pharmaceuticals Key News & Latest Developments
Table 70. Abbvie Corporate Summary
Table 71. Abbvie Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 72. Abbvie Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 73. Abbvie Key News & Latest Developments
Table 74. AbCellera Corporate Summary
Table 75. AbCellera Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 76. AbCellera Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 77. AbCellera Key News & Latest Developments
Table 78. ABL Bio Corporate Summary
Table 79. ABL Bio Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 80. ABL Bio Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 81. ABL Bio Key News & Latest Developments
Table 82. Abpro Corporate Summary
Table 83. Abpro Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 84. Abpro Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 85. Abpro Key News & Latest Developments
Table 86. Academy of Military Medical Sciences (China) Corporate Summary
Table 87. Academy of Military Medical Sciences (China) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 88. Academy of Military Medical Sciences (China) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 89. Academy of Military Medical Sciences (China) Key News & Latest Developments
Table 90. Accellix Corporate Summary
Table 91. Accellix Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 92. Accellix Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 93. Accellix Key News & Latest Developments
Table 94. Accord Healthcare Corporate Summary
Table 95. Accord Healthcare Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 96. Accord Healthcare Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 97. Accord Healthcare Key News & Latest Developments
Table 98. AccuGenomics Corporate Summary
Table 99. AccuGenomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 100. AccuGenomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 101. AccuGenomics Key News & Latest Developments
Table 102. ACEA Biosciences Corporate Summary
Table 103. ACEA Biosciences Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 104. ACEA Biosciences Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 105. ACEA Biosciences Key News & Latest Developments
Table 106. AC Immune Corporate Summary
Table 107. AC Immune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 108. AC Immune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 109. AC Immune Key News & Latest Developments
Table 110. Acoustic MedSystems Corporate Summary
Table 111. Acoustic MedSystems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 112. Acoustic MedSystems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 113. Acoustic MedSystems Key News & Latest Developments
Table 114. Adaptimmune Corporate Summary
Table 115. Adaptimmune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 116. Adaptimmune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 117. Adaptimmune Key News & Latest Developments
Table 118. Aduro BioTech Corporate Summary
Table 119. Aduro BioTech Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 120. Aduro BioTech Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 121. Aduro BioTech Key News & Latest Developments
Table 122. Advaxis Corporate Summary
Table 123. Advaxis Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 124. Advaxis Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 125. Advaxis Key News & Latest Developments
Table 126. Adventus Ventures Corporate Summary
Table 127. Adventus Ventures Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 128. Adventus Ventures Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 129. Adventus Ventures Key News & Latest Developments
Table 130. Aerolase Corporate Summary
Table 131. Aerolase Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offerings
Table 132. Aerolase Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$, Mn) & (2020-2025)
Table 133. Aerolase Key News & Latest Developments
List of Figures
Figure 1. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Picture
Figure 2. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Segment by Type in 2024
Figure 3. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Segment by Application in 2024
Figure 4. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Overview: 2024
Figure 5. Key Caveats
Figure 6. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size: 2024 VS 2032 (US$, Mn)
Figure 7. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue: 2020-2032 (US$, Mn)
Figure 8. The Top 3 and 5 Players Market Share by Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in 2024
Figure 9. Segmentation by Type � Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2024 & 2032
Figure 10. Segmentation by Type - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share, 2020-2032
Figure 11. Segmentation by Application � Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2024 & 2032
Figure 12. Segmentation by Application - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share, 2020-2032
Figure 13. By Region - Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share, 2020-2032
Figure 14. By Country - North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share, 2020-2032
Figure 15. United States Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2032
Figure 16. Canada Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2032
Figure 17. Mexico Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2032
Figure 18. By Country - Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share, 2020-2032
Figure 19. Germany Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2032
Figure 20. France Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2032
Figure 21. U.K. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2032
Figure 22. Italy Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2032
Figure 23. Russia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2032
Figure 24. Nordic Countries Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2032
Figure 25. Benelux Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2032
Figure 26. By Region - Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share, 2020-2032
Figure 27. China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2032
Figure 28. Japan Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2032
Figure 29. South Korea Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2032
Figure 30. Southeast Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2032
Figure 31. India Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2032
Figure 32. By Country - South America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share, 2020-2032
Figure 33. Brazil Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2032
Figure 34. Argentina Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2032
Figure 35. By Country - Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share, 2020-2032
Figure 36. Turkey Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2032
Figure 37. Israel Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2032
Figure 38. Saudi Arabia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2032
Figure 39. UAE Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, (US$, Mn), 2020-2032
Figure 40. 1ST Biotherapeutics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 41. 3B Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 42. 3D-Micromac Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 43. 3DMed Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 44. 3D Systems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 45. 10X Genomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 46. A*STAR Agency for Science Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 47. Technology and Research Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 48. A*STAR Institute of Microelectronics (IME) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 49. A2A Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 50. Abbvie Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 51. AbCellera Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 52. ABL Bio Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 53. Abpro Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 54. Academy of Military Medical Sciences (China) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 55. Accellix Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 56. Accord Healthcare Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 57. AccuGenomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 58. ACEA Biosciences Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 59. AC Immune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 60. Acoustic MedSystems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 61. Adaptimmune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 62. Aduro BioTech Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 63. Advaxis Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 64. Adventus Ventures Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 65. Aerolase Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
